SAN DIEGO, May 6, 2014 (GLOBE NEWSWIRE) -- Celladon Corporation (Nasdaq: CLDN ), a clinical-stage biotechnology company developing novel therapies for patients with heart failure and other diseases characterized by SERCA enzyme deficiencies, today announced that it will report its results for the first quarter ended March 31, 2014 on Tuesday, May 13, 2014. The company will also hold a live investor conference call and webcast at 4:30pm Eastern/1:30pm Pacific on Tuesday, May 13, 2014.
| Conference Call & Webcast | |
| Tuesday, May 13, 2014 @ 4:30pm Eastern Time/1:30pm Pacific Time | |
| Domestic: | 855-455-6053 |
| International: | 484-756-4307 |
| Conference ID: | 42429335 |
| Webcast: | www.celladon.net |
| Replays – Available through June 12, 2014 | |
| Domestic: | 855-859-2056 |
| International: | 404-537-3406 |
| Conference ID: | 42429335 |
About Celladon Corporation
Celladon, a clinical-stage biotechnology company, is a leader in the field of calcium dysregulation. The Company is targeting SERCA enzymes to develop novel therapies for diseases with significant unmet medical needs, such as heart failure. Its therapeutic portfolio for diseases characterized by SERCA enzyme deficiency includes both gene therapies and small molecule compounds. MYDICAR(R), its most advanced product candidate, uses gene therapy to target SERCA2a, an enzyme that is deficient in heart failure patients. Its small molecule platform of SERCA2b modulators includes a number of potential first-in-class compounds that address novel targets in diabetes and neurodegenerative diseases. For more information, visit www.celladon.com .
Forward-Looking Statements
Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements regarding Celladon's plans to research, develop and commercialize product candidates. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon Celladon's current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks and uncertainties associated with the process of conducting product development activities and clinical trials and obtaining regulatory approval to commercialize product candidates, Celladon's reliance on third parties, the need to raise additional funding when needed in order to conduct Celladon's business, and the degree of market acceptance of MYDICAR by physicians, patients, third-party payors and others in the medical community. These and other risks and uncertainties are described more fully in Celladon's filings with the Securities and Exchange Commission, including without limitation its Annual Report on Form 10-K for the year ended December 31, 2013. All forward-looking statements contained in this press release speak only as of the date on which they were made. Celladon undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.
Fredrik Wiklund Vice President, Corporate Development and Investor Relations (858) 432-7215
